NasdaqCM:LFVN

Stock Analysis Report

Executive Summary

LifeVantage Corporation engages in the identification, research, development, and distribution of nutraceutical dietary supplements and personal care products.

Snowflake

Fundamentals

Flawless balance sheet with proven track record.

Risks

  • LifeVantage is not covered by any analysts.

Similar Companies

Share Price & News

How has LifeVantage's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

6.4%

LFVN

-1.8%

US Personal Products

-0.6%

US Market


1 Year Return

16.8%

LFVN

11.3%

US Personal Products

0.6%

US Market

LFVN outperformed the Personal Products industry which returned 11.7% over the past year.

LFVN outperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

LFVNIndustryMarket
7 Day6.4%-1.8%-0.6%
30 Day17.5%-3.5%2.2%
90 Day21.9%0.9%1.1%
1 Year16.8%16.8%13.0%11.3%2.9%0.6%
3 Year30.2%30.2%43.2%35.7%44.6%35.2%
5 Year67.3%67.3%81.6%62.7%61.9%44.2%

Price Volatility Vs. Market

How volatile is LifeVantage's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is LifeVantage undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

LifeVantage's share price is below the future cash flow value, and at a moderate discount (> 20%).

LifeVantage's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

LifeVantage is overvalued based on earnings compared to the US Personal Products industry average.

LifeVantage is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for LifeVantage, we can't assess if its growth is good value.


Price Based on Value of Assets

LifeVantage is overvalued based on assets compared to the US Personal Products industry average.


Next Steps

Future Growth

How is LifeVantage expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

5.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if LifeVantage is high growth as no revenue estimate data is available.

LifeVantage's earnings are expected to grow by 5.5% yearly, however this is not considered high growth (20% yearly).

Unable to compare LifeVantage's revenue growth to the United States of America market average as no estimate data is available.

LifeVantage's earnings growth is positive but not above the United States of America market average.

LifeVantage's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if LifeVantage will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has LifeVantage performed over the past 5 years?

-17.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

LifeVantage's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.

LifeVantage's 1-year earnings growth exceeds its 5-year average (29% vs -17.4%)

LifeVantage's earnings growth has exceeded the US Personal Products industry average in the past year (29% vs 21.4%).


Return on Equity

LifeVantage has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

LifeVantage used its assets more efficiently than the US Personal Products industry average last year based on Return on Assets.


Return on Capital Employed

LifeVantage's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is LifeVantage's financial position?


Financial Position Analysis

LifeVantage is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

LifeVantage's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

LifeVantage's level of debt (5.3%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (739.4% vs 5.3% today).

Debt is well covered by operating cash flow (1223.5%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 30.4x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 29.7x debt.


Next Steps

Dividend

What is LifeVantage's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate LifeVantage's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate LifeVantage's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as LifeVantage has not reported any payouts.

Unable to verify if LifeVantage's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as LifeVantage has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of LifeVantage's salary, the management and board of directors tenure and is there insider trading?

3.5yrs

Average management tenure


CEO

Darren Jensen (50yo)

4.3yrs

Tenure

US$1,258,840

Compensation

Mr. Darren Jay Jensen has been the Chief Executive Officer and President of Lifevantage Corp. since May 18, 2015 and has been its Director since January 8, 2016. From June 2014 to May 2015, Mr. Jensen serv ...


CEO Compensation Analysis

Darren's remuneration is about average for companies of similar size in United States of America.

Darren's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.5yrs

Average Tenure

50.5yo

Average Age

The tenure for the LifeVantage management team is about average.


Board Age and Tenure

2.6yrs

Average Tenure

58yo

Average Age

The average tenure for the LifeVantage board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$19,83030 Nov 18
Raymond Greer
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,500
Max PriceUS$13.22
BuyUS$13,73127 Nov 18
Garry Mauro
EntityIndividual
Role
Chairman of the Board
Chairman
Shares1,150
Max PriceUS$11.94

Ownership Breakdown


Management Team

  • Eric Marchant

    Vice President of Compliance

    • Tenure: 0yrs
  • Steven Fife (58yo)

    Chief Financial Officer

    • Tenure: 2.5yrs
    • Compensation: US$518.19k
  • Darren Jensen (50yo)

    President

    • Tenure: 4.3yrs
    • Compensation: US$1.26m
  • Justin Rose (51yo)

    Chief Sales Officer

    • Tenure: 4.2yrs
    • Compensation: US$614.50k
  • Michelle Oborn-Virchow (39yo)

    Senior Vice President of Human Resources

    • Tenure: 3.8yrs
    • Compensation: US$627.21k
  • Kevin McMurray

    General Counsel

    • Tenure: 2yrs
    • Compensation: US$725.34k
  • Ryan Goodwin (42yo)

    Chief Marketing Officer

    • Tenure: 3.9yrs
    • Compensation: US$541.81k
  • Dave Fleming

    Senior Vice President of Global Field Development - Americas & Europe

    • Tenure: 3.2yrs
  • Chuck Wach (57yo)

    Chief Operating Officer

    • Tenure: 2.5yrs
    • Compensation: US$572.31k
  • Chris Taylor

    Director of Communications

    • Tenure: 0yrs

Board Members

  • Michael Beindorff (67yo)

    Independent Director

    • Tenure: 7.7yrs
    • Compensation: US$133.35k
  • Ray Greer (56yo)

    Independent Director

    • Tenure: 2.6yrs
    • Compensation: US$201.70k
  • Darwin Lewis (60yo)

    Independent Director

    • Tenure: 2.6yrs
    • Compensation: US$204.20k
  • Garry Mauro (71yo)

    Chairman

    • Tenure: 5.8yrs
    • Compensation: US$142.85k
  • Darren Jensen (50yo)

    President

    • Tenure: 4.3yrs
    • Compensation: US$1.26m
  • Vinayak Hegde (49yo)

    Independent Director

    • Tenure: 2.6yrs
    • Compensation: US$201.70k
  • Erin Brockovich

    Director

    • Tenure: 0.3yrs

Company Information

LifeVantage Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: LifeVantage Corporation
  • Ticker: LFVN
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: US$196.782m
  • Shares outstanding: 14.12m
  • Website: https://www.lifevantage.com

Number of Employees


Location

  • LifeVantage Corporation
  • 9785 South Monroe Street
  • Suite 400
  • Sandy
  • Utah
  • 84070
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LFVNNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDOct 2004
L2T1DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2004

Biography

LifeVantage Corporation engages in the identification, research, development, and distribution of nutraceutical dietary supplements and personal care products. The company offers Protandim, a line of scien ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 00:05
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.